Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with rare diseases. The company's lead product candidate is amikacin liposome inhalation suspension, which is in late-state development for adult patients with treatment refractory nontuberculous mycobacteria lung disease caused by mycobacterium avium complex. Its earlier-stage clinical pipeline also includes INS1007, an oral reversible inhibitor of dipeptidyl peptidase 1 for non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug for rare pulmonary disorders. The company was founded in 1999 and is headquartered in Bridgewater, New Jersey.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone908-977-9900
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees214
OptionableOptionable
Insmed (NASDAQ:INSM) Frequently Asked Questions
What is Insmed's stock symbol?
Insmed trades on the NASDAQ under the ticker symbol "INSM."
How were Insmed's earnings last quarter?
Insmed Incorporated (NASDAQ:INSM) released its quarterly earnings data on Tuesday, October, 30th. The biopharmaceutical company reported ($1.14) earnings per share for the quarter, missing the consensus estimate of ($1.06) by $0.08. View Insmed's Earnings History.
When is Insmed's next earnings date?
What price target have analysts set for INSM?
7 brokerages have issued 12-month price targets for Insmed's stock. Their predictions range from $22.00 to $43.00. On average, they anticipate Insmed's share price to reach $35.2857 in the next twelve months. This suggests a possible upside of 30.3% from the stock's current price. View Analyst Price Targets for Insmed.
What is the consensus analysts' recommendation for Insmed?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insmed in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Insmed.
Has Insmed been receiving favorable news coverage?
Headlines about INSM stock have been trending positive recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Insmed earned a media sentiment score of 2.3 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the company's share price in the near term.
Who are some of Insmed's key competitors?
Some companies that are related to Insmed include Ionis Pharmaceuticals (IONS), Beigene (BGNE), Jazz Pharmaceuticals (JAZZ), SAGE Therapeutics (SAGE), Nektar Therapeutics (NKTR), Loxo Oncology (LOXO), Marina Biotech (MRNA), Perrigo (PRGO), Catalent (CTLT), Dr.Reddy's Laboratories (RDY), Amarin (AMRN), GALAPAGOS NV/S (GLPG), United Therapeutics (UTHR), Patheon (PTHN) and Alkermes (ALKS).
Who are Insmed's key executives?
Insmed's management team includes the folowing people:
- Mr. William H. Lewis, Pres, CEO & Chairman (Age 50)
- Ms. Christine A. Pellizzari, Chief Legal Officer (Age 51)
- Mr. Roger Adsett, Chief Commercial Officer (Age 50)
- Dr. Paul Streck, Chief Medical Officer (Age 56)
- Mr. Paolo Tombesi, Chief Financial Officer (Age 55)
Who are Insmed's major shareholders?
Insmed's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Foresite Capital Management IV LLC (2.56%), Northern Trust Corp (1.22%), Geode Capital Management LLC (1.12%), Bellevue Group AG (1.05%), Dimensional Fund Advisors LP (1.02%) and Emerald Advisers LLC (0.78%). Company insiders that own Insmed stock include Alfred Altomari, Christine A Pellizzari, Donald J Hayden Jr, Melvin Md Sharoky, Orlov S Nicole Schaeffer, Roger Adsett, Steinar J Engelsen and William Lewis. View Institutional Ownership Trends for Insmed.
Which major investors are selling Insmed stock?
INSM stock was sold by a variety of institutional investors in the last quarter, including Emerald Mutual Fund Advisers Trust, Emerald Advisers LLC, Northern Trust Corp, TD Asset Management Inc., Los Angeles Capital Management & Equity Research Inc., Squarepoint Ops LLC, California Public Employees Retirement System and MetLife Investment Advisors LLC. Company insiders that have sold Insmed company stock in the last year include Alfred Altomari and Orlov S Nicole Schaeffer. View Insider Buying and Selling for Insmed.
Which major investors are buying Insmed stock?
INSM stock was acquired by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Bellevue Group AG, Foresite Capital Management IV LLC, Geode Capital Management LLC, Hudson Bay Capital Management LP, Alps Advisors Inc., Rhumbline Advisers and Raymond James & Associates. Company insiders that have bought Insmed stock in the last two years include Christine A Pellizzari, Melvin Md Sharoky, Roger Adsett, Steinar J Engelsen and William Lewis. View Insider Buying and Selling for Insmed.
How do I buy shares of Insmed?
Shares of INSM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Insmed's stock price today?
One share of INSM stock can currently be purchased for approximately $27.07.
How big of a company is Insmed?
Insmed has a market capitalization of $2.09 billion. The biopharmaceutical company earns $-192,640,000.00 in net income (profit) each year or ($2.89) on an earnings per share basis. Insmed employs 214 workers across the globe.
What is Insmed's official website?
How can I contact Insmed?
Insmed's mailing address is 10 Finderne Avenue Building 10, Bridgewater NJ, 08807. The biopharmaceutical company can be reached via phone at 908-977-9900 or via email at [email protected]
MarketBeat Community Rating for Insmed (NASDAQ INSM)
MarketBeat's community ratings are surveys of what our community members think about Insmed and other stocks. Vote "Outperform" if you believe INSM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INSM will underperform the S&P 500 over the long term. You may vote once every thirty days.
